|
US4018653A
(en)
|
1971-10-29 |
1977-04-19 |
U.S. Packaging Corporation |
Instrument for the detection of Neisseria gonorrhoeae without culture
|
|
US4016043A
(en)
|
1975-09-04 |
1977-04-05 |
Akzona Incorporated |
Enzymatic immunological method for the determination of antigens and antibodies
|
|
US4275149A
(en)
|
1978-11-24 |
1981-06-23 |
Syva Company |
Macromolecular environment control in specific receptor assays
|
|
US4318980A
(en)
|
1978-04-10 |
1982-03-09 |
Miles Laboratories, Inc. |
Heterogenous specific binding assay employing a cycling reactant as label
|
|
US4424279A
(en)
|
1982-08-12 |
1984-01-03 |
Quidel |
Rapid plunger immunoassay method and apparatus
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
|
US5182368A
(en)
|
1986-06-13 |
1993-01-26 |
Ledbetter Jeffrey A |
Ligands and methods for augmenting B-cell proliferation
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5700637A
(en)
|
1988-05-03 |
1997-12-23 |
Isis Innovation Limited |
Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5874082A
(en)
|
1992-07-09 |
1999-02-23 |
Chiron Corporation |
Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
|
|
EP0751781B1
(en)
|
1993-12-23 |
2004-05-26 |
Immunex Corporation |
Use of monoclonal antibodies or soluble oligomeric ligands in the manufacture of a medicament for the prevention or treatment of neoplastic disorders
|
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
|
GB9425060D0
(en)
|
1994-12-13 |
1995-02-08 |
Univ Birmingham |
Carcinoma treatment
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
DE19544393A1
(de)
|
1995-11-15 |
1997-05-22 |
Hoechst Schering Agrevo Gmbh |
Synergistische herbizide Mischungen
|
|
EP1500329B1
(en)
|
1996-12-03 |
2012-03-21 |
Amgen Fremont Inc. |
Human antibodies that specifically bind human TNF alpha
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
US6248535B1
(en)
*
|
1999-12-20 |
2001-06-19 |
University Of Southern California |
Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
|
|
WO2001075166A2
(en)
|
2000-03-31 |
2001-10-11 |
Genentech, Inc. |
Compositions and methods for detecting and quantifying gene expression
|
|
AU2001259215A1
(en)
|
2000-04-28 |
2001-11-12 |
La Jolla Institute For Allergy And Immunology |
Human anti-cd40 antibodies and methods of making and using same
|
|
IL157946A0
(en)
|
2001-04-02 |
2004-03-28 |
Genentech Inc |
Combination therapy
|
|
JP4025881B2
(ja)
|
2001-04-27 |
2007-12-26 |
キリンファーマ株式会社 |
抗ｃｄ４０モノクローナル抗体
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
CA2515096A1
(en)
|
2003-02-06 |
2004-08-26 |
Genomic Health, Inc. |
Gene expression markers for response to egfr inhibitor drugs
|
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
|
EP2157524A3
(en)
|
2003-09-03 |
2010-12-08 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
|
ATE474598T1
(de)
|
2003-11-04 |
2010-08-15 |
Novartis Vaccines & Diagnostic |
Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
|
|
PT1694360E
(pt)
|
2003-11-04 |
2010-12-13 |
Novartis Vaccines & Diagnostic |
Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
|
|
CA2563074C
(en)
*
|
2004-04-09 |
2014-05-20 |
Genomic Health, Inc. |
Gene expression markers for predicting response to chemotherapy
|
|
WO2006125117A2
(en)
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
|
|
WO2006125143A2
(en)
*
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
|
|
CA2609269C
(en)
|
2005-05-26 |
2014-08-05 |
Seattle Genetics, Inc. |
Humanized anti-cd40 antibodies and their methods of use
|
|
CA2611728A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with cancer therapy
|
|
WO2007032743A2
(en)
*
|
2005-09-16 |
2007-03-22 |
Biovator Technologies Ab |
In vitro assay for identification of allergenic proteins
|
|
DE102005052384B4
(de)
*
|
2005-10-31 |
2009-09-24 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
|
|
EP1968636A4
(en)
|
2005-12-09 |
2010-06-02 |
Seattle Genetics Inc |
METHOD OF USE OF CD40 BONDING AGENTS
|
|
US7527774B2
(en)
|
2005-12-22 |
2009-05-05 |
Basf Catalysts Llc |
Inlet metallic foam support coupled to precious metal catalyst for application on 4 stroke platforms
|
|
WO2007082379A2
(en)
*
|
2006-01-20 |
2007-07-26 |
Mcgill University |
Method to identify cd40-sensitive cells using gene expression
|
|
WO2008079269A2
(en)
|
2006-12-19 |
2008-07-03 |
Genego, Inc. |
Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
|
|
MX2010005080A
(es)
|
2007-11-07 |
2010-07-28 |
Genentech Inc |
Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
|